Adjuvant oestrogen therapy does not improve disease activity in postmenopausal patients with rheumatoid arthritis. 1993

H R van den Brink, and A A van Everdingen, and M J van Wijk, and J W Jacobs, and J W Bijlsma
Department of Rheumatology, University Hospital Utrecht, The Netherlands.

OBJECTIVE To investigate whether oestrogens can be used as treatment to diminish disease activity in women with rheumatoid arthritis. METHODS Forty postmenopausal female patients with active rheumatoid arthritis participated in a placebo-controlled, double-blind study on the possible beneficial effect of adjuvant treatment of oestradiol on disease activity. RESULTS Thirty three patients completed 52 weeks of treatment with 2 mg oestradiol-valerate or placebo. No statistically significant difference was found in and between both treatment groups with regard to articular indices, pain score by visual analogue scale, erythrocyte sedimentation rate and health questionnaire on daily activities before, during and at the end of the study. CONCLUSIONS This first randomised prospective placebo-controlled study shows no beneficial effect of oestrogens on disease activity in postmenopausal female patients with rheumatoid arthritis.

UI MeSH Term Description Entries
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D010352 Patient Dropouts Discontinuance of care received by patient(s) due to reasons other than full recovery from the disease. Dropout, Patient,Dropouts, Patient,Patient Dropout
D001799 Blood Sedimentation Measurement of rate of settling of ERYTHROCYTES in blood. Erythrocyte Sedimentation,Erythrocyte Sedimentation Rate,Erythrocyte Sedimentation Rates,Rate, Erythrocyte Sedimentation,Rates, Erythrocyte Sedimentation,Sedimentation Rate, Erythrocyte,Sedimentation Rates, Erythrocyte,Sedimentation, Blood,Sedimentation, Erythrocyte
D004311 Double-Blind Method A method of studying a drug or procedure in which both the subjects and investigators are kept unaware of who is actually getting which specific treatment. Double-Masked Study,Double-Blind Study,Double-Masked Method,Double Blind Method,Double Blind Study,Double Masked Method,Double Masked Study,Double-Blind Methods,Double-Blind Studies,Double-Masked Methods,Double-Masked Studies,Method, Double-Blind,Method, Double-Masked,Methods, Double-Blind,Methods, Double-Masked,Studies, Double-Blind,Studies, Double-Masked,Study, Double-Blind,Study, Double-Masked
D004359 Drug Therapy, Combination Therapy with two or more separate preparations given for a combined effect. Combination Chemotherapy,Polychemotherapy,Chemotherapy, Combination,Combination Drug Therapy,Drug Polytherapy,Therapy, Combination Drug,Chemotherapies, Combination,Combination Chemotherapies,Combination Drug Therapies,Drug Polytherapies,Drug Therapies, Combination,Polychemotherapies,Polytherapies, Drug,Polytherapy, Drug,Therapies, Combination Drug
D004958 Estradiol The 17-beta-isomer of estradiol, an aromatized C18 steroid with hydroxyl group at 3-beta- and 17-beta-position. Estradiol-17-beta is the most potent form of mammalian estrogenic steroids. 17 beta-Estradiol,Estradiol-17 beta,Oestradiol,17 beta-Oestradiol,Aerodiol,Delestrogen,Estrace,Estraderm TTS,Estradiol Anhydrous,Estradiol Hemihydrate,Estradiol Hemihydrate, (17 alpha)-Isomer,Estradiol Monohydrate,Estradiol Valerate,Estradiol Valeriante,Estradiol, (+-)-Isomer,Estradiol, (-)-Isomer,Estradiol, (16 alpha,17 alpha)-Isomer,Estradiol, (16 alpha,17 beta)-Isomer,Estradiol, (17-alpha)-Isomer,Estradiol, (8 alpha,17 beta)-(+-)-Isomer,Estradiol, (8 alpha,17 beta)-Isomer,Estradiol, (9 beta,17 alpha)-Isomer,Estradiol, (9 beta,17 beta)-Isomer,Estradiol, Monosodium Salt,Estradiol, Sodium Salt,Estradiol-17 alpha,Estradiol-17beta,Ovocyclin,Progynon-Depot,Progynova,Vivelle,17 beta Estradiol,17 beta Oestradiol,Estradiol 17 alpha,Estradiol 17 beta,Estradiol 17beta,Progynon Depot
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly
D000893 Anti-Inflammatory Agents Substances that reduce or suppress INFLAMMATION. Anti-Inflammatory Agent,Antiinflammatory Agent,Agents, Anti-Inflammatory,Agents, Antiinflammatory,Anti-Inflammatories,Antiinflammatories,Antiinflammatory Agents,Agent, Anti-Inflammatory,Agent, Antiinflammatory,Agents, Anti Inflammatory,Anti Inflammatories,Anti Inflammatory Agent,Anti Inflammatory Agents

Related Publications

H R van den Brink, and A A van Everdingen, and M J van Wijk, and J W Jacobs, and J W Bijlsma
May 2008, British journal of clinical pharmacology,
H R van den Brink, and A A van Everdingen, and M J van Wijk, and J W Jacobs, and J W Bijlsma
November 1996, Annals of the rheumatic diseases,
H R van den Brink, and A A van Everdingen, and M J van Wijk, and J W Jacobs, and J W Bijlsma
January 2022, Rheumatology advances in practice,
H R van den Brink, and A A van Everdingen, and M J van Wijk, and J W Jacobs, and J W Bijlsma
July 2015, Rheumatology (Oxford, England),
H R van den Brink, and A A van Everdingen, and M J van Wijk, and J W Jacobs, and J W Bijlsma
August 2008, British journal of clinical pharmacology,
H R van den Brink, and A A van Everdingen, and M J van Wijk, and J W Jacobs, and J W Bijlsma
July 2006, Nature clinical practice. Oncology,
H R van den Brink, and A A van Everdingen, and M J van Wijk, and J W Jacobs, and J W Bijlsma
January 2019, Clinical and experimental rheumatology,
H R van den Brink, and A A van Everdingen, and M J van Wijk, and J W Jacobs, and J W Bijlsma
January 2005, Arthritis research & therapy,
H R van den Brink, and A A van Everdingen, and M J van Wijk, and J W Jacobs, and J W Bijlsma
January 2009, Clinical and experimental rheumatology,
H R van den Brink, and A A van Everdingen, and M J van Wijk, and J W Jacobs, and J W Bijlsma
May 2015, Rheumatology international,
Copied contents to your clipboard!